VitaNova Life Sciences (VNOV) Net Income towards Common Stockholders (2017 - 2026)
VitaNova Life Sciences' (VNOV) quarterly Net Income towards Common Stockholders came in at -$96508.0 in Q3 2026, down 108.44% YoY from $1.1 million in Q3 2025, and down 649.93% on a QoQ basis from $17549.0 in Q2 2026.
Powered by 
Analysis
VitaNova Life Sciences (VNOV) Net Income towards Common Stockholders (2017 - 2026) Analysis & Trends
VitaNova Life Sciences has disclosed Net Income towards Common Stockholders across 10 years of filings, most recently posting -$96508.0 for Q3 2026.
- Net Income towards Common Stockholders for Q3 2026 came in at -$96508.0, down 108.44% year-over-year; the trailing twelve-month figure through Jul 2026 was -$87511.0 (down 110.18% YoY), and the FY2026 annual result was -$37304.0, down 104.38% from the prior year.
- Net Income towards Common Stockholders for Q3 2026 stood at -$96508.0, down from $17549.0 in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $800332.0 in Q2 2025 and bottomed at -$96508.0 in Q3 2026.
- Average Net Income towards Common Stockholders over 5 years is $42930.6, with a median of $2134.0 recorded in 2022.
- The widest annual swing landed in 2023, when Net Income towards Common Stockholders plunged 1236.22%; it then soared 3929.4% in 2024.
- Year by year, Net Income towards Common Stockholders stood at $2601.0 in 2022, then plunged by 436.6% to -$8755.0 in 2023, then soared by 472.9% to $32647.0 in 2024, then grew by 9.69% to $35810.0 in 2025, then slumped by 369.5% to -$96508.0 in 2026.
- The last three Net Income towards Common Stockholders figures came in at -$96508.0 (Q3 2026), $17549.0 (Q2 2026), and -$44362.0 (Q1 2026), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Accenture | 120.96 Bn | 111.91 Bn | 6.13 Bn | 2.39 Bn |
| 2 | UL Solutions | 12.94 Bn | 12.53 Bn | 417.00 Mn | 254.00 Mn |
| 3 | Gartner | 11.74 Bn | 10.25 Bn | 1.19 Bn | 275.50 Mn |
| 4 | Booz Allen Hamilton Holding | 9.28 Bn | 8.74 Bn | 1.46 Bn | 198.00 Mn |
| 5 | Tetra Tech | 9.14 Bn | 8.91 Bn | 243.21 Mn | 109.58 Mn |
| 6 | Genpact | 5.74 Bn | 5.22 Bn | 490.34 Mn | 145.74 Mn |
| 7 | Grand Canyon Education | 3.97 Bn | 3.69 Bn | 204.08 Mn | 45.85 Mn |
| 8 | Fti Consulting | 3.91 Bn | 3.74 Bn | 316.27 Mn | 57.81 Mn |
| 9 | Korn Ferry | 3.90 Bn | 3.09 Bn | 681.29 Mn | 69.50 Mn |
| 10 | VitaNova Life Sciences | 11.51 Mn | 9.90 Mn | 30,521.00 | -96,508.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Apr 30, 2026 | 17,549.00 |
| Jan 31, 2026 | -44,362.00 |
| Oct 31, 2025 | 35,810.00 |
| Jul 31, 2025 | -46,301.00 |
| Apr 30, 2025 | 800,332.00 |
| Jan 31, 2025 | 72,978.00 |
| Oct 31, 2024 | 32,647.00 |
| Jul 31, 2024 | -55,211.00 |
| Apr 30, 2024 | 167,919.00 |
| Jan 31, 2024 | 5,948.00 |
| Oct 31, 2023 | -8,755.00 |
| Jul 31, 2023 | -24,247.00 |
| Apr 30, 2023 | -4,385.00 |
| Jan 31, 2023 | -24,577.00 |
| Oct 31, 2022 | 2,601.00 |
| Jul 31, 2022 | 2,134.00 |
| Apr 30, 2022 | -26,807.00 |
| Jan 31, 2022 | 8,917.00 |
| Oct 31, 2021 | 15,009.00 |
| Jul 31, 2021 | 142,563.00 |